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Abstract 
A 65-year-old man presented to our hospital with abdominal pain, dyspepsia and anorexia. 
Laboratory tests showed an altered liver function and abdomen ultrasonography revealed 
multiple liver nodules, suspected to be metastatic lesions. Serous tumor markers were 
elevated and a very high level of alpha-fetoprotein was found. Computer tomography 
confirmed the hepatic lesions and disclosed a thickening of the lesser curvature of the gastric 
wall. A subsequent endoscopy showed an ulcer on the lesser curvature. Biopsies taken from 
the gastric ulcer and the liver nodule revealed an adenocarcinoma, both of gastric origin. 
Shortly after the diagnosis, the patient’s condition worsened and he died only 15 days later. 
This case report illustrates how alpha-fetoprotein-producing gastric adenocarcinomas have a 
high incidence of venous and lymphatic invasion and a rapid hepatic spread with a very poor 
prognosis. © 2014 S. Karger AG, Basel 
Case Presentation 
In September 2011, a 65-year-old Caucasian man was admitted to our hospital after a 1-
month history of epigastric pain, dyspepsia, and anorexia. He had been treated with a 
proton-pump inhibitor for 2 months. He had a history of type 2 diabetes mellitus, arterial 
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hypertension, and dyslipidemia. At physical examination, intense abdominal pain in the 
upper abdominal quadrants was noted. Laboratory tests showed elevated aspartate 
transaminase 107 U/l (reference range 10–40 U/l), alanine transaminase 89 U/l (reference 
range 10–40 U/l), gamma-glutamyl transpeptidase 627 U/l (reference range 10–40 U/l) and 
alkaline phosphatase 309 U/l (reference range 40–130 U/l); total bilirubin was 1.07 mg/dl 
(reference range 0.3–1.0 mg/dl). Ultrasonography showed a remarkable and irregular 
enlargement of the liver with multiple and diffuse nodules in the right hepatic lobe (the 
largest measured 5 cm in diameter) and a unique large mass (15 × 9 cm) in the left lobe. 
Abdomen computer tomography scans showed multiple nodules in the liver, suspected to be 
metastatic lesions, portal vein thrombosis, multiple adenopathies along the lesser curvature 
of the stomach, the mesenteric root and the lombo-aortic region as well as a thickening of 
the gastric lesser curvature wall (fig. 1 a, b). Tumor markers were: alpha-fetoprotein (AFP) 
209093 U/ml (reference range 0–10 U/ml), Ca 19.9 170,5 U/ml (reference range 0–39 
U/ml), and Ca 125 52,2 U/ml (reference range 035 U/ml); other markers were found to be in 
a normal range, in particular CEA and Ca 72.4. Markers for hepatitis B and C were negative 
(HBsAg, HBV-DNA and HCV IgG). An esophagogastroduodenoscopy showed a 4 cm ulcer on 
the lesser curvature of the stomach (fig. 2). At the pathologic examination, the biopsy 
revealed a gastric adenocarcinoma. The biopsy of one of the hepatic nodules showed a 
poorly differentiated adenocarcinoma, similar to that of a gastric biopsy. Immunohistochem-
ical findings showed a positivity for CAM 5.2, CDX 2 CK 20 and a negativity for CD10, TTF1, 
sinaptophysin and chromogranin A, therefore supporting a diagnosis of metastasis of gastric 
adenocarcinoma (fig. 3). One week later, the patient’s condition quickly worsened (Perfor-
mance Status 3 in accordance with the European Cooperative Oncology Group scale). He 
presented jaundice, abdominal pain and, at palpation, the appearance of a solid mass in the 
left upper quadrant of the abdomen and liver enlargement. Levels of transaminases, gamma-
glutamyl transpeptidase and alkaline-phosphatase increased; total bilirubin was 19.6 mg/dl 
and the conjugated one was 12.8 mg/dl. Abdominal ultrasonography showed, with respect 
to the previous one, an increased number and size of the hepatic nodules as well as a biliary 
tract dilatation. Tumor markers were found to be increased further: AFP 470396 U/ml, Ca 
19.9 354.0 U/ml, and Ca 125 113.7 U/ml. A chemotherapeutic approach was excluded due to 
the patient’s poor condition, his performance status and the altered liver function tests. The 
patient was discharged and received the best possible supportive care. He died 15 days later. 
Discussion 
Gastric adenocarcinoma is a neoplasm with a frequent association to various tumor 
markers such as Ca 72.4, CEA and Ca 19.9. In our case report, elevated serum AFP levels 
were present in a patient with gastric adenocarcinoma and liver metastases. AFP is a well-
known embryonic serum protein, produced by fetal liver cells, yolk sac cells and some fetal 
gastrointestinal cells [1]. The elevation of serum AFP, in conjunction with the hepatic lesions, 
may be associated with hepatocellular carcinoma or germ-cell tumors. However, AFP can be 
produced exceptionally by gastrointestinal tract organs [1], the lung [2], the bladder [3] and 
by renal cancers [4]. For diseases such as chronic hepatitis, liver cirrhosis and hepatocellular 
carcinoma, the level of AFP is a good predictor of disease progression and outcome, as it is 
directly correlated to disease progression [5, 6]. 
Gastric cancer with the capability of releasing AFP is called AFP-producing gastric carci-
noma, first described by Boureille et al. [7] in 1970. Only a few cases have been reported 
with an incidence rate of 2.7–8.0% of all gastric malignant tumors [8]. The majority of cases 
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described in the literature refer to Asian people [9]. Our case is one of the few European 
cases of AFP-producing gastric carcinomas. However, the serum AFP level does not 
necessarily correlate with tumor size, stage or prognosis [6, 8, 10]. In our case, elevated 
serum levels of AFP and his quick increase were associated with a rapid disease progression 
and a fatal outcome. 
Cases of AFP-producing gastric cancers are characterized by a poor prognosis, a high 
incidence of venous invasion, by lymph node and liver metastases and even T1 tumors 
(according to the TNM staging system) [5]. The exact molecular mechanisms explaining this 
aggressive behavior is still unclear. Possible causes of liver metastases have been hypothe-
sized in the hepatic capability to develop a suitable environment for the cancer cells growth 
and to promote an early vascular invasion [5]. 
Conclusions 
AFP-producing gastric cancers are a small subgroup of gastric cancers, with a high like-
lihood of rapid hepatic metastasization. We think that further studies, especially on a cellular 
and molecular level, are necessary to explain the highly aggressive biological behavior of 
AFP-producing gastric cancers in order to develop an effective multimodal and targeted 
therapy. 
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Fig. 1. Computer tomography image of metastatic lesions in the liver (a, b). 
 
 
 
Fig. 2. Esophagogastroduodenoscopy image of a bleeding gastric ulcer (see arrow). 
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Fig. 3. Histologic evaluation of the hepatic biopsy. 
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